Early trial tests new combo for Tough-to-Treat breast cancer
NCT ID NCT05064085
Summary
This early-stage study is testing the safety of combining two drugs—an oral chemotherapy called capecitabine and an immunotherapy drug called cemiplimab—for people with advanced hormone-positive breast cancer. The main goal is to find the safest and most effective dose for future studies. It involves a small group of patients to see how well they tolerate the treatment and if it helps control their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.